Report Summary

Introduction
The model provides a comprehensive analysis of the mAb market, forecasting its commercial evolution out to 2012 and assessing trends by product, company, therapy area, technology and target type. It also provides an insight into the direction of mAb technology evolution and an analysis of pipeline dynamics.

Reasons to Purchase
Assess the key products that will drive sales growth in the mAb market to 2012
Analyze historical and forecast sales for all mAb products in the PharmaVitae universe
Assess all pipeline mAbs currently in development from pre-clinical testing to pre-registration